The development of new anti-inflammatory therapeutics usually entails the assessment of drug efficacy in disease models. Determining the potential effects on multiple parameters of the inflammatory response offers clear benefits at early stages of discovery programmes. We offer a vast series of validated models, as well as more sophisticated approaches to assess the anti-inflammatory potential of new candidates. Several transgenic models (many exclusive to us) are also available.
These models are short-duration models for the study of the molecular and cellular mediators of inflammation and very convenient for the screening of new anti-inflammatory molecules.
FEATURED DISEASE MODELS:
Paw oedema
A solution of carrageenan in saline injected into the hind footpad induces an acute swelling of the paw that becomes maximal approximately 3 hours after the injection.
Air-pouch
The murine air pouch model provides a contained compartment, that has been likened to the synovial cavity, in which to study the inflammatory response and leukocyte trafficking.
Peritonitis
Peritonitis is induced with 1mg of zymosan administered intra-peritoneally, and assessment of affects are conducted after 4 hours.
Systemic inflammation remains a significant clinical challenge as it frequently results in multi-organ dysfunction, leading to high mortality rates. Animal models are required for the development of new therapeutic options and identification of potential drug candidates
FEATURED DISEASE MODELS:
Endotoxaemia
The model consists of injection of purified lipopolysaccharide (LPS) intra-peritoneally.
Caecal-Ligation and Puncture
The CLP model of sepsis involves performance of a laparotomy under general anesthesia followed by ligation of a portion of the cecum in conjunction with creation of one or more cecal colotomies via needle puncture.
Splanchnic Ischaemia-reperfusion injury
The occlusion and reperfusion of the splanchnic arteries provokes local and systemic alterations principally derived from the release of cytotoxic substances and the interaction between neutrophils and endothelial cells.
Rheumatoid arthritis occurs when the body's immune system targets affected joints, which leads to pain, swelling and joint destruction in the long term. Animal models are used to identify mechanisms of disease and for the development of novel therapies.
FEATURED DISEASE MODEL:
K/BxN serum induced arthritis
K/BxN serum model of inflammatory arthritis is an aggressive model that mimics the active phases of rheumatoid arthritis, with a fast onset, ideal for drug testing.
Collagen-induced arthritis
Autoimmune arthritis is induced in this model by immunisation with an emulsion of complete Freund's adjuvant and type II collagen (CII).
Adjuvant-induced arthritis
The disease induced in this model is a T cell-mediated autoimmune arthritis that is frequently used to study immunological aspects of rheumatoid arthritis.
Experimental animal models of specific organ dysfunction, such as heart failure or inflammatory bowel disease, are commonly used during the pre-clinical phase of drug development for the identification of novel therapeutic targets and for the development of new drugs.
FEATURED DISEASE MODEL:
Acute myocardial infarction
The model consists on the ligation of the left anterior descending coronary artery (LAD), preventing blood flow and forming an area of ischemia.
DSS colitis model
Intestinal inflammation is induced by administering 5% dextran sulphate sodium in drinking water, which disrupts the epithelial monolayer resulting in exposure of the underlying immune system to the intestinal microbiota.
Please contact us for more information on any of these models, to obtain a proposal or to arrange to speak with one of our scientists.
Our cookies
We use cookies, which are small text files, to improve your experience on our website.
You can allow or reject non essential cookies or manage them individually.
Our cookies
We use cookies, which are small text files, to improve your experience on our website. You can allow all or manage them individually.
You can find out more on our cookie page at any time.